T-cell lymphomas are a relatively uncommon form of non-Hodgkin lymphoma, accounting for 10-15% of all non-Hodgkin Lymphomas, and presents diagnostic and therapeutic challenges to the pathologist and clinician alike. In recent years, there have been several advances in the understanding of the molecular biology and genomics of disease resulting in insights with diagnostic, prognostic, and even therapeutic implications. The poor outcome of most T-cell lymphomas further underscores the need for biomarkers to guide the clinical management of these patients. A prime example is the discovery of DUSP22-IRF4 or TP63 rearrangements in ALK-negative Anaplastic large cell lymphoma which portend favorable and poor risk respectively. The use of targeted therapy for surface (Brentuximab and Alemtuzumab) and intracellular (HDAC inhibitors, proteasome inhibitors) in T-cell lymphoma are informed by the molecular biology of disease and highlight the need for further research and awareness in this unique category of hematologic neoplasms.
This article collection aims to review our scientific understanding of T-cell lymphoma. Given the number of recent genomic and experimental studies in this space, we aim to provide comprehensive reviews on the genomics/molecular biology of T-cell lymphoma as well including original articles which will provide a basis for refining and further developing our understanding of the biology of T cell lymphomas/leukemia with attendant prognostic and therapeutic implications. Special focus will be given, but not limited to, the following
areas of research:
· Whole exome sequencing of Sezary syndrome
· Clinical MRD testing using NGS in cutaneous T-cell lymphoma
· Genomics of Anaplastic large cell lymphoma (to include DUSP22/TP63)
· Current and upcoming molecular diagnostic modalities for T-cell lymphoma
· Updates on intestinal T-cell lymphoma with a focus on genomics
· Genetic landscape of rare subtypes of cutaneous T-cell lymphoma
· HTLV genomic integration by NGS in ATLL
· Genomic interrogation of Peripheral T-cell lymphoma cell lymphomas with an atypical indolent course
We welcome original research, reviews, mini-reviews, methods, and clinical trial articles.
T-cell lymphomas are a relatively uncommon form of non-Hodgkin lymphoma, accounting for 10-15% of all non-Hodgkin Lymphomas, and presents diagnostic and therapeutic challenges to the pathologist and clinician alike. In recent years, there have been several advances in the understanding of the molecular biology and genomics of disease resulting in insights with diagnostic, prognostic, and even therapeutic implications. The poor outcome of most T-cell lymphomas further underscores the need for biomarkers to guide the clinical management of these patients. A prime example is the discovery of DUSP22-IRF4 or TP63 rearrangements in ALK-negative Anaplastic large cell lymphoma which portend favorable and poor risk respectively. The use of targeted therapy for surface (Brentuximab and Alemtuzumab) and intracellular (HDAC inhibitors, proteasome inhibitors) in T-cell lymphoma are informed by the molecular biology of disease and highlight the need for further research and awareness in this unique category of hematologic neoplasms.
This article collection aims to review our scientific understanding of T-cell lymphoma. Given the number of recent genomic and experimental studies in this space, we aim to provide comprehensive reviews on the genomics/molecular biology of T-cell lymphoma as well including original articles which will provide a basis for refining and further developing our understanding of the biology of T cell lymphomas/leukemia with attendant prognostic and therapeutic implications. Special focus will be given, but not limited to, the following
areas of research:
· Whole exome sequencing of Sezary syndrome
· Clinical MRD testing using NGS in cutaneous T-cell lymphoma
· Genomics of Anaplastic large cell lymphoma (to include DUSP22/TP63)
· Current and upcoming molecular diagnostic modalities for T-cell lymphoma
· Updates on intestinal T-cell lymphoma with a focus on genomics
· Genetic landscape of rare subtypes of cutaneous T-cell lymphoma
· HTLV genomic integration by NGS in ATLL
· Genomic interrogation of Peripheral T-cell lymphoma cell lymphomas with an atypical indolent course
We welcome original research, reviews, mini-reviews, methods, and clinical trial articles.
